Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 7/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.35 |
| ▸ | PLK4 | O00444 | 2/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.34 |
| ▸ | KDR | P35968 | 3/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CSGALNACT1 | Q8TDX6 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL162644 | 0.89 | DGAT1 (0.47) | DGAT1RIPK1NTRK1KDRKIT | |
| SCHEMBL162367 | 0.87 | DGAT1 (0.47) | DGAT1KDRKITMEN1MAPT | |
| SCHEMBL162252 | 0.87 | DGAT1 (0.48) | DGAT1NTRK1KDRKITMEN1 | |
| SCHEMBL161878 | 0.85 | DGAT1 (0.52) | DGAT1RIPK1KDRKITMAPT | |
| SCHEMBL161990 | 0.84 | DGAT1 (0.51) | DGAT1RIPK1PLK4NTRK1KDR | |
| SCHEMBL160684 | 0.84 | DGAT1 (0.49) | DGAT1RIPK1NTRK1KDRKIT | |
| SCHEMBL161575 | 0.82 | LOXL2 (0.36) | — | |
| SCHEMBL164633 | 0.82 | DGAT1 (0.50) | DGAT1RIPK1PLK4KDRKIT | |
| SCHEMBL162302 | 0.79 | ALDH1A1 (0.41) | MEN1LMNAMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL162001 | 0.77 | DGAT1 (0.47) | DGAT1RIPK1PLK4KDRKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611783-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-07-10 | — | — | EP | claimed |
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-06-20 | — | — | US | claimed |
| WO-2012029032-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | claimed |
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | DGAT1, DGAT2, SOAT1 | DGAT1 1/4885RIPK1 3390/4885PLK4 2751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.